DepemokimabasthmaGSKNCT04719832NCT04718103St George's Respiratory Questionnaire
… in patients on medium- vs high-dose ICS (figure 1).Conclusions Depemokimab reduces exacerbations in patfients with asthma across baseline …
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 721–780 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
Dapsone5Diclofenac5Epirubicin5FibroScan5Hyperbaric bupivacaine5ICB5ICS/LABA5IFNγ5IL-185SARS-CoV-25donanemab5immunomodulators5low-dose aspirin5tapentadol5thiazolidinediones56-mercaptopurine5High-dose steroids5JAK inhibitors5Letrozole5Mercaptopurine5Steroid5Trastuzumab Emtansine5Vitamin B125antiseizure medication5candesartan5ganciclovir5immune checkpoint inhibitor5non-steroidal anti-inflammatory drug5normal saline5nortriptyline5supplemental oxygen5ASMs5Atracurium5Bacillus Calmette-Guérin5Bendamustine5High-dose intravenous methylprednisolone5SF-365Selective Serotonin Reuptake Inhibitors5acetic acid5contraceptives5delpar5intravenous ceftriaxone5liposomal amphotericin B5prescription opioids5topical corticosteroids5venlafaxine5DPP4i4ELA4Estrogen4Rilvegostomig4HM163904Alectinib4Penumbra4RP14LEvoSimendan4Nipocalimab4Dinutuximab4SEL4BLM4IL-17i4
Articles mentioning drugs
10,506 articles · page 176 of 876TEPP-46apigeninPulmonary arterial hypertensionPAHcancer
…flavone suppressor of the Warburg effect, and a PKM2 activator, TEPP-46, were used to manipulate the PTPB1-PKM2 axis both in this cell …
dupilumabchronic obstructive pulmonary diseaseCOPDtype 2 inflammationtriple inhalation therapyBOREASNCT03930732
…erbation rates were observed regardless of baseline IgE levels (dupilumab: 0.56 [95% CI:0.50–0.63] for 100 IU/mL to 0.53 [0.44–0.63] for …
Mepolizumabchronic obstructive pulmonary diseaseSciurbaFlynnCOPD-HELPinhaled corticosteroidsCOPDAECOPDNEJM
…Background Mepolizumab, a monoclonal antibody to interleukin-5, has been shown to redu…
RvD1Chronic Obstructive Pulmonary DiseaseCOPD
…RvD1 treated group (1.1 vs 0.8 fold change, p=0.044).Conclusion RvD1 ameliorated the inflammatory cytokine response to HI in COPD M-…
apixabanVKADOACDOAC-antiplateletAtrial fibrillation
…e majority (64.4%) of patients received reduced DOAC doses with apixaban prescribed in 40.7%. In 39 (14.4%) patients, antithrombotic use…
edaravoneamyotrophic lateral sclerosisALSStudy19ALS-Functional-Rating-Scale-RevisedStudy16Pharmaceutical Benefits SchemePBSNCT00330681
…n the rate of decline was 2.98 (95% CI 1.67, 4.29) in favour of edaravone, a clinically important 40% reduction versus placebo. Safety an…
18F-FDG-PETendometrial cancerinfective endocarditisESUS
… a two-year period. Patients admitted with ESUS who received an 18F-FDG-PET were included in the study and underwent case note review for c…
pyridoxinevitamin B6motor neuron disease (MND)MND
…doxine supplementation further suggests the utility of checking pyridoxine levels in the context of\ clinical presentations associated wit…
TolebrutinibnrSPMSsecondary progressive MSNCT04411641
…Background Tolebrutinib, a brain-penetrant, bioactive, Bruton’s tyrosine kinase inhibit…
DuloxetinechemotherapyCIPN
…otherapy cessation and chronic, disabling neuropathic symptoms. Duloxetine has previously demonstrated efficacy for symptom relief, howeve…
cannabis
…) youth and young adults has declined from historic levels, but cannabis use has not. The importance of cannabis use as a risk factor fo…